Department of Chemistry and Manchester Institute of Biotechnology, The University of Manchester, 131 Princess Street, Manchester, M1 7DN, United Kingdom.
Natural and Medical Sciences Research Center, University of Nizwa, P.O Box 33, Postal Code 616 Birkat Al Mauz, Nizwa, Oman.
Int J Biol Macromol. 2021 Jan 15;167:233-244. doi: 10.1016/j.ijbiomac.2020.11.170. Epub 2020 Nov 27.
Diabetes mellitus, a progressive chronic disease, characterized by the abnormal carbohydrate metabolism is associated with severe health complications including long term dysfunction or failure of several organs, cardiovascular and micro-angiopathic problems (neuropathy, nephropathy, retinopathy). Despite the existence of diverse chemical structural libraries of α-glucosidase inhibitors, the limited diabetic treatment due to the adverse side effects such as abdominal distention, flatulence, diarrhoea, and liver damage associated with these inhibitors encourage the medicinal research community to design and develop new and potent inhibitors of α-glucosidase with better pharmacokinetic properties. In this perspective, we demonstrate the successful integration of common functional groups (ketone & ester) in one combined pharmacophore which is favorable for the formation of hydrogen bonds and other weaker interactions with the target proteins. These keto ester derivatives were screened for their α-glucosidase inhibition potential and the in vitro results revealed compound 3c as the highly active inhibitor with an IC value of 12.4 ± 0.16 μM compared to acarbose (IC = 942 ± 0.74 μM). This inhibition potency was ~76-fold higher than acarbose. Other potent compounds were 3f (IC = 28.0 ± 0.28 μM), 3h (IC = 33.9 ± 0.09 μM), 3g (IC = 34.1 ± 0.04 μM), and 3d (IC = 76.5 ± 2.0 μM). In addition, the emerging use of carbonic anhydrase inhibitors for the treatment of diabetic retinopathy (a leading cause of vision loss) prompted us to screen the keto ester derivatives for the inhibition of carbonic anhydrase-II. Compound 3b was found significantly active against carbonic anhydrase-II with an IC of 16.5 ± 0.92 μM (acetazolamide; IC = 18.2 ± 1.23 μM). Compound 3a also exhibited comparable potency with an IC value of 18.9 ± 1.08 μM. Several structure-activity relationship analyses depicted the influence of the substitution pattern on both the aromatic rings. Molecular docking analysis revealed the formation of several H-bonding interactions through the ester carbonyl and the nitro oxygens of 3c with the side chains of His348, Arg212 and His279 in the active pocket of α-glucosidase whereas 3b interacted with His95, -OH of Thr197, Thr198 and WAT462 in the active site of carbonic anhydrase-II. Furthermore, evaluation of ADME properties suggests the safer pharmacological profile of the tested derivatives.
糖尿病是一种渐进性的慢性疾病,其特征是碳水化合物代谢异常,与严重的健康并发症有关,包括长期功能障碍或多个器官衰竭、心血管和微血管病变(神经病变、肾病、视网膜病变)。尽管存在多种α-葡萄糖苷酶抑制剂的化学结构库,但由于这些抑制剂会引起腹部胀气、气胀、腹泻和肝损伤等不良反应,限制了糖尿病的治疗,这促使药物研究界设计和开发新的、有效的、具有更好药代动力学特性的α-葡萄糖苷酶抑制剂。在这方面,我们成功地将常见的功能基团(酮和酯)整合到一个组合的药效基团中,这有利于与靶蛋白形成氢键和其他较弱的相互作用。对这些酮酯衍生物进行了α-葡萄糖苷酶抑制潜力的筛选,体外结果显示,化合物 3c 是一种高度活性抑制剂,IC 值为 12.4 ± 0.16 μM,而阿卡波糖(IC = 942 ± 0.74 μM)。这种抑制活力比阿卡波糖高约 76 倍。其他有效化合物为 3f(IC = 28.0 ± 0.28 μM)、3h(IC = 33.9 ± 0.09 μM)、3g(IC = 34.1 ± 0.04 μM)和 3d(IC = 76.5 ± 2.0 μM)。此外,碳酸酐酶抑制剂在治疗糖尿病性视网膜病变(视力丧失的主要原因)方面的新应用促使我们筛选酮酯衍生物对碳酸酐酶-II 的抑制作用。化合物 3b 对碳酸酐酶-II 的抑制作用显著,IC 值为 16.5 ± 0.92 μM(乙酰唑胺;IC = 18.2 ± 1.23 μM)。化合物 3a 也表现出相当的效力,IC 值为 18.9 ± 1.08 μM。多项构效关系分析描述了取代模式对两个芳环的影响。分子对接分析表明,化合物 3c 通过酯羰基和硝基氧与α-葡萄糖苷酶活性口袋中 His348、Arg212 和 His279 的侧链形成了几个氢键相互作用,而 3b 则与碳酸酐酶-II 的活性位点中的 His95、-OH 的 Thr197、Thr198 和 WAT462 相互作用。此外,对 ADME 特性的评估表明,所测试衍生物具有更安全的药理学特性。